Free Trial Information
BioCentury | Mar 3, 2021
Product Development

Verdine’s FogPharma to bring lead cell-permeable peptide into clinic with $107M series C

FogPharma will use its venBio-led $107 million series C round to bring its lead program, a cell-permeable CTNNB1 antagonist, into the clinic for cancer. The company, helmed by Chairman, President...
Read More
BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

With crossover investors lining up to participate, biotechs Immuneering, Terns and Ikena each raised rounds that could augur upcoming public offerings. The deals come as a host of biotechs will likely...
Read More
BioCentury | Jun 27, 2020
Translation in Brief

Regeneron enhances checkpoint therapy with CD28 bispecifics; plus NIH funds Alzheimer’s brain mapping, Genentech and more

Regeneron combines CD28 bispecifics with PD-1 mAb In its latest paper covering anti-CD28 bispecific antibodies, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) showed in Science Translational Medicine that the bispecifics could boost anti-PD-1 efficacy. Bispecifics against CD28 and...
Read More
BioCentury | Apr 5, 2019
Targets & Mechanisms

Breaking up Hippo to tame proliferation

...TEAD4 is the major isoform driving hepatoblastoma. And a pair of 2018 studies suggested the YAP-TEAD4...
...TEA domain family member 2 TEAD3 - TEA domain family member 3 TEAD4 - TEA domain family member 4...
...MST1) TEA domain family member 1 (TEAD1) TEA domain family member 2 (TEAD2) TEA domain family member 3 (TEAD3) TEA domain family member 4 (TEAD4) Yes-associated...
Read More
BioCentury | Jan 15, 2019
Distillery Therapeutics

Cancer

...INDICATION: Brain cancer Cell culture experiments suggest inhibiting TEAD4-YAP1 binding interactions with flufenamic acid-based compounds could...
...binds TEAD2, in vitro testing and optimization of hits yielded a compound that inhibited the TEAD4-YAP1...
...Next steps could include testing the TEAD4-YAP1 binding inhibitors in mouse models of glioblastoma. TARGET/MARKER/PATHWAY: TEA domain family member 4 (TEAD4)...
Read More
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

...member 1; TEAD2 -TEA domain family member 2; TEAD3 -TEA domain family member 3; TEAD4 -TEA domain family member 4...
Read More
BioCentury | Sep 14, 2017
Targets & Mechanisms

Platelets YAP at cancer

While elevated platelet levels often signify an underlying malignancy, the molecular mechanisms linking the two are not well understood. Now, a team from MD Anderson has shown a well-known, but barely exploited signaling pathway mediates...
Read More
Items per page:
1 - 7 of 7